- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01116843
Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment
July 8, 2015 updated by: University Health Network, Toronto
A Preoperative Window of Opportunity Study to Assess the Modulation of Biomarkers in the Primary Tumor Site of Patients With Resectable Oral Cavity Cancer (OCC) Randomized to Receive Preoperative Treatment With PF-00299804
The objective of this study is to assess the biological effects in the primary tumor following a short, pre-operative course of treatment with PF-00298804 in patients with Oral Cavity Cancer.
Study Overview
Detailed Description
This is a single-center, randomized, double-blinded, biomarker driven, preoperative window of opportunity study with a pharmacodynamic primary endpoint.
Patients with resectable, histologically confirmed OCC for whom surgical treatment is planned as definitive management, will be randomized 2:1 to receive PF-00299804 pre-operatively at a dose of 45 mg once daily orally for 7-11 days or to Matching Placebo for 7-11 days depending on surgery schedule.
The target is a total of 8 days of treatment but with a minimum of 7 and a maximum of 11 dosing days.
All patients will receive surgery as per standard of care without delay.
Biomarkers from the surgical specimen and baseline tumor biopsy or consent to provide a tumor block from existing primary diagnostic tumor biopsy completed within 90 days will be evaluated for primary and secondary pharmacodynamic endpoints.
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed, voluntary informed consent provided
- Willing and able to comply with scheduled visits, treatment plan, tests, other study procedures
- Patient must be diagnosed with histologically confirmed oral cavity squamous cell carcinoma (OCC) (lip, floor of mouth, anterior 2/3 tongue, buccal mucosa, upper and lower gingiva, hard palate and retromolar trigone) considered resectable (T1-4a, N0-2, M0; (without distant metastases)) for whom surgical resection of tumor is planned. Patients with distant metastatic disease or diagnosis of SCCHN may not be enrolled
- Must be able to provide a fresh tumor biopsy prior to randomization for histopathological and biomarker evaluation. No anti-neoplastic treatment allowed between obtaining baseline tumor specimen and randomization. Patients who decline an in-house fresh pre-treatment tumor biopsy must give consent to provide a tumor block from an existing diagnostic primary tumor biopsy completed within 90 days of enrolment
- Prior treatment with agents targeted to epidermal growth factor receptor is not allowed.
- No prior chemotherapy or radiotherapy (to primary site/nodes).
- Patient must not have received prior anti-neoplastic treatment within past 2 years
- Any treatment-related acute toxicity, including laboratory abnormalities, must have recovered to CTCAE Grade 1 (v.4.0) or baseline, except toxicity not considered a safety risk.
- ECOG performance status of 0-2.
- Patient must have adequate organ function as determined by the following criteria:
- Serum creatinine ≤ 1.5 ULN or a calculated creatinine clearance of ≥ 50 mL/min
- Absolute neutrophil count ≥ 1.5 x 109/L
- Leukocytes > 3.0 x 109/L
- Hemoglobin > 80 g/L
- Platelets > 100 x 109/L
- Total bilirubin < ULN
- AST (SGOT) and ALT (SGPT) < 2.5 x ULN
- 12-Lead ECG with normal tracing, or clinically non-significant changes that do not require medical intervention
- QTc interval < 470 msec, and without history of Torsades de Pointes or other symptomatic QTc abnormality
- A normal LVEF of >50% as measured by ECHO or MUGA within 4 weeks prior to start of study treatment will be required for all patients
Exclusion Criteria:
- Patients who require segmental mandibulectomy for surgical resection of oral cavity tumor will not be enrolled
- Primary site of head and neck carcinoma in nasopharynx, skin, or unknown
- Prior or concurrent radiation therapy to tumor at site of planned resection
- Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of PF-00299804
- Requirement for treatment with drugs that are highly dependent on CYP2D6 for metabolism since PF-00299804 is a potent CYP2D6 inhibitor in in vitro assays
- Patients currently taking drugs that have a risk of causing Torsades de Pointes
- Any acute or chronic medical, psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or trial drug administration or could interfere with interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry in the trial
- Other serious uncontrolled medical disorder or active infection that would impair the ability to receive study treatment as determined by investigator
- Dementia or significantly altered mental status that would limit the ability to obtain informed consent and compliance with the requirements of this protocol
- Patients breastfeeding or pregnant are excluded. All female patients with reproductive potential must have a negative pregnancy test within 72 hours prior to treatment.
- Patients of reproductive potential or their partners must agree to use effective contraception while receiving trial treatment and for at least 3 months thereafter.
- Current enrollment in another therapeutic clinical trial
- Inability/lack of willingness to comply with visits, treatment plans, protocol assessments or laboratory tests
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PF-00299804
Patient will receive PF-00299804 pre-operatively at a dose of 45 mg once daily orally for 7-11 days depending on surgery schedule.
|
PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.
Other Names:
|
Placebo Comparator: Placebo arm
Patient will receive matching Placebo for 7-11 days depending on surgery schedule.
|
PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the degree of modulation of the proliferation index, ki-67, in the primary tumor of OCC specimens following a short, preoperative course of PF-00299804
Time Frame: 8-11 months
|
8-11 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate changes in tissue and blood-based biomarkers before, during and after treatment with PF-00299804 and attempt to correlate with gene expression changes, EGFR variant III mutation status, EGFR amplification and histopathological changes
Time Frame: 8-11 months
|
8-11 months
|
To assess the relationship between pharmacokinetic parameters and molecular changes detected in OCC tumor specimens
Time Frame: 8-11 months
|
8-11 months
|
To assess the safety and tolerability of pre-operative PF-00299804
Time Frame: 8-11 months
|
8-11 months
|
To quantitatively assess the effect of PF-00299804 on tumorigenic cells expressing CD44+/Lin- markers in paired OCC tumor specimens
Time Frame: 8-11 months
|
8-11 months
|
To evaluate gene expression changes in tumor tissue before and after treatment with PF00299804
Time Frame: 8-11 months
|
8-11 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Lillian Siu, MD, FRCPC, Princess Margaret Hospital, Canada
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (Actual)
February 1, 2012
Study Completion (Actual)
February 1, 2014
Study Registration Dates
First Submitted
May 3, 2010
First Submitted That Met QC Criteria
May 4, 2010
First Posted (Estimate)
May 5, 2010
Study Record Updates
Last Update Posted (Estimate)
July 10, 2015
Last Update Submitted That Met QC Criteria
July 8, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- WS590266
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Cavity Cancer
-
University of WashingtonBlaze Bioscience Inc.RecruitingStage III Lip and Oral Cavity Cancer AJCC v8 | Oral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Stage IVA Lip and Oral Cavity Cancer AJCC v8United States
-
Ohio State University Comprehensive Cancer CenterCompletedTongue Cancer | Lip and Oral Cavity Squamous Cell Carcinoma | Oral Cavity Verrucous Carcinoma | Stage 0 Lip and Oral Cavity CancerUnited States
-
National Cancer Institute (NCI)CompletedLip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Stage 0 Lip and Oral Cavity Cancer | Stage 0 Oropharyngeal CancerUnited States
-
National Cancer Institute (NCI)CompletedLip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Oral LeukoplakiaUnited States
-
Medical University of South CarolinaBristol-Myers SquibbCompletedOral Cavity SCCUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingTongue Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Verrucous Carcinoma of the Larynx | Recurrent Verrucous Carcinoma of the Oral Cavity | Recurrent Adenoid... and other conditionsUnited States
-
University Hospital, Basel, SwitzerlandRecruitingOral Cavity Defect | Oropharynx DefectSwitzerland
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedLocally Advanced Resectable Oral Cavity Squamous Cell CancerItaly
-
Centre Hospitalier Universitaire DijonCompletedCancerous Lesions of the Oral CavityFrance
-
National Cancer Institute (NCI)Dana-Farber Cancer InstituteWithdrawnHead and Neck Cancer | Lip and Oral Cavity Cancer | Oropharyngeal CancerUnited States
Clinical Trials on PF-00299804
-
PfizerCompleted
-
PfizerCompletedNeoplasmsUnited States, Netherlands
-
Yonsei UniversityCompletedHead Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell MetastaticKorea, Republic of
-
PfizerCompleted
-
University Health Network, TorontoPfizerCompletedHead and Neck Squamous Cell CarcinomaCanada
-
PfizerTerminatedNon-Small Cell Lung Cancer (NSCLC)United States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...PfizerCompletedCarcinoma, Squamous Cell | Penile NeoplasmsItaly
-
PfizerCompletedCarcinoma, Non-small CellUnited States, Taiwan, Korea, Republic of, Japan, Hong Kong
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...UnknownSkin Squamous Cell CancerItaly
-
NCIC Clinical Trials GroupPfizerCompletedLung CancerTaiwan, Canada, Australia, Italy, New Zealand, United States, Thailand, Korea, Republic of, Brazil, Argentina, Philippines, Peru